|
Q3 FY2026
As of Feb 28, 2026
|
Q2 FY2026
As of Nov 30, 2025
|
Q1 FY2026
As of Aug 31, 2025
|
Q4 FY2025
As of May 31, 2025
|
Q3 FY2025
As of Feb 28, 2025
|
Q2 FY2025
As of Nov 30, 2024
|
Q1 FY2025
As of Aug 31, 2024
|
Q4 FY2024
As of May 31, 2024
|
Q3 FY2024
As of Feb 29, 2024
|
Q2 FY2024
As of Nov 30, 2023
|
Q1 FY2024
As of Aug 31, 2023
|
Q4 FY2023
As of May 31, 2023
|
Q3 FY2023
As of Feb 28, 2023
|
Q2 FY2023
As of Nov 30, 2022
|
Q1 FY2023
As of Aug 31, 2022
|
Q4 FY2022
As of May 31, 2022
|
Q3 FY2022
As of Feb 28, 2022
|
Q2 FY2022
As of Nov 30, 2021
|
Q1 FY2022
As of Aug 31, 2021
|
Q4 FY2021
As of May 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accrued interest | ||||||||||||||||||||
| Due to related party | ||||||||||||||||||||
| Convertible notes | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| Common Stock: $0.001 par value, 75,000,000 shares authorized, 606,475 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders' Deficit | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
Loading...
